Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Michael Jon Pishvaian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1165-9041; OpenAlex author ID A5021453899. Sources: ClinicalTrials.gov.

Their work

Papers
60 (first author 4, last author 8)
Trials
8 (principal investigator on 3)
Grants
0
Labs led
3
Collaborators
250
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 trial · 2012: 1 paper, 1 trial · 2013: 1 paper · 2014: 3 papers, 1 trial · 2015: 2 papers · 2016: 2 papers, 1 trial · 2017: 5 papers · 2018: 6 papers, 2 trials · 2019: 5 papers · 2020: 9 papers · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 10 papers · 2026: 5 papers, 1 trial

Papers 50 of 60

  1. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  2. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  3. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  4. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  5. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  6. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  7. Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics. First author DOI 10.1016/j.semradonc.2025.08.004↗
  8. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  9. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  10. Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cance… Co-author DOI 10.1186/s40164-025-00673-0↗
  11. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  12. Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1200/jco-25-01040↗
  13. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  14. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  15. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. Co-author DOI 10.1200/po-24-00684↗
  16. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… Co-author DOI 10.1002/cncr.35479↗
  17. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  18. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Co-author DOI 10.2217/fon-2023-0963↗
  19. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad178↗
  20. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  21. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a … Co-author DOI 10.3389/fonc.2023.1250136↗
  22. Anti-Ro60 Antibodies Utility as a Diagnostic Indicator of Pancreatic Cancer: A Case Report. First author DOI 10.1097/mpa.0000000000002202↗
  23. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  24. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  25. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  26. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. Co-author DOI 10.1200/po.20.00494↗
  27. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Last author DOI 10.1002/cam4.3011↗
  28. Upfront molecular profiling of pancreatic cancer patients - An idea whose time has come. Last author DOI 10.1016/j.pan.2020.01.017↗
  29. The economic burden of metastatic pancreatic cancer. Last author DOI 10.1016/j.pan.2020.09.002↗
  30. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  31. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Last author DOI 10.1089/pancan.2020.0005↗
  32. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1136/esmoopen-2019-000668↗
  33. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  34. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Co-author DOI 10.1172/jci136760↗
  35. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinom… First author DOI 10.1634/theoncologist.2020-0321↗
  36. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1089/pancan.2019.0003↗
  37. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  38. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Last author DOI 10.1158/1535-7163.mct-19-0208↗
  39. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  40. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Co-author DOI 10.1200/po.19.00115↗
  41. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s12029-016-9909-2↗
  42. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Co-author DOI 10.1080/15384047.2016.1210743↗
  43. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedur… Co-author DOI 10.1089/pancan.2018.0015↗
  44. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  45. Molecular Profiling of Pancreatic Cancer Patients-Response. Co-author DOI 10.1158/1078-0432.ccr-18-2645↗
  46. Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. Co-author DOI 10.1200/po.18.00039↗
  47. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Co-author DOI 10.1038/bjc.2017.40↗
  48. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000118↗
  49. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.17.00016↗
  50. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Kno… Co-author DOI 10.18632/oncotarget.13225↗

Trials 8

  1. The Canopy Cancer Collective Clinical Registry Protocol Study chair NCT07605702↗
  2. Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Study chair NCT03257033↗
  3. Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Study chair NCT03376659↗
  4. Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer Study chair NCT02967770↗
  5. Study of Gemcitabine and Abraxane for Pancreas Cancer Principal investigator NCT02242409↗
  6. Molecularly Tailored Therapy for Pancreas Cancer Principal investigator NCT01888978↗
  7. ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Study chair NCT01489865↗
  8. A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer Principal investigator NCT01051284↗

Closest collaborators

The 25 strongest of 250 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 19 shared papers, 2015–2026 · strength 1.92
  2. Daniel A. Laheru · 9 shared papers, 2017–2026 · strength 1.60
  3. Emanuel F. Petricoin · 8 shared papers, 2018–2025 · strength 1.02
  4. Dung Thi Le · 5 shared papers, 2022–2026 · strength 0.99
  5. Harshabad Singh · 5 shared papers, 2024–2026 · strength 0.93
  6. Andrew Eugene Hendifar · 7 shared papers, 2017–2025 · strength 0.86
  7. Charles J. Yeo · 8 shared papers, 2016–2025 · strength 0.83
  8. Elizabeth M. Jaffee · 4 shared papers, 2025–2026 · strength 0.78
  9. Lynn McCormick Matrisian · 7 shared papers, 2017–2025 · strength 0.71
  10. Lei Zheng · 4 shared papers, 2022–2026 · strength 0.71
  11. Andrew J. Aguirre · 4 shared papers, 2024–2025 · strength 0.69
  12. Lei Zheng · 3 shared papers, 2024–2025 · strength 0.68
  13. Arsen Osipov · 3 shared papers, 2025–2026 · strength 0.66
  14. John Lindsay Marshall · 9 shared papers, 2013–2020 · strength 0.64
  15. Eileen Mary O'Reilly · 4 shared papers, 2021–2026 · strength 0.63
  16. Brian Matthew Wolpin · 4 shared papers, 2021–2025 · strength 0.59
  17. Rachna T. Shroff · 3 shared papers, 2024–2025 · strength 0.56
  18. Richard Andrew Burkhart · 3 shared papers, 2022–2026 · strength 0.55
  19. Maria Farooq · 1 shared paper, 2025 · strength 0.54
  20. Ana De Jesus‐Acosta · 3 shared papers, 2022–2024 · strength 0.54
  21. Aiwu Ruth He · 7 shared papers, 2014–2020 · strength 0.53
  22. Kenneth H. Yu · 3 shared papers, 2025–2026 · strength 0.51
  23. Benjamin Adam Weinberg · 5 shared papers, 2014–2024 · strength 0.50
  24. Valerie Lee · 3 shared papers, 2022–2026 · strength 0.50
  25. Rosalie C. Sears · 2 shared papers, 2025–2026 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.